<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679302</url>
  </required_header>
  <id_info>
    <org_study_id>14415</org_study_id>
    <nct_id>NCT00679302</nct_id>
  </id_info>
  <brief_title>Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management</brief_title>
  <official_title>A Double Blinded Randomized Controlled Trial for the Management of Pediatric Community Acquired Skin Abscesses - To Treat or Not to Treat With Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if antibiotics are required in the management of
      skin abscess following incision and drainage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized controlled trial at an urban pediatric emergency
      department. Sample size (162) was based on a threshold equivalence of 7% (Î± = 0.05, power =
      80%). Inclusion criteria were: non-toxic, immunocompetent, 3 months to 18 years old,
      English-speaking patients with clinical or ultrasound identified skin abscesses who were not
      on antibiotics. Patients were block randomized to receive placebo or
      trimethoprim/sulfamethoxazole following incision and drainage. Follow-up was a call at 2-3
      days &amp; a repeat visit or call at 10-14 days. Treatment failure was defined as: persistent
      erythema, tenderness, and/or draining lesions. New lesion was defined as: primary resolution
      with development of new lesion (furuncle, carbuncle or abscess) at a different location.
      Compliance was evaluated by the return of the study medication or by patient report.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin Abscess Resolution</measure>
    <time_frame>10-14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>New Lesion Development and Spread of Skin Abscesses (on Subject)</measure>
    <time_frame>10-14 days and 3 month</time_frame>
    <description>The secondary outcomes of interest included the development of new lesions at a different site (&gt;5cm away from original skin abscess) on day 10 clinical follow-up or self-report and 3 month telephone follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Skin Diseases, Infectious</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maalox and bitter mixture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antibiotic group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trimethoprim-sulfamethoxazole suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-sulfamethoxazole</intervention_name>
    <description>Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.</description>
    <arm_group_label>antibiotic group</arm_group_label>
    <other_name>Septra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.</description>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>Maalox (with simethicone and bitter mixture)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-toxic patients

          -  immunocompetent patients

          -  3 months to 18 years old

          -  English-speaking patients

          -  skin abscesses

          -  not on antibiotics

        Exclusion Criteria:

          -  toxic patients

          -  immunocompromising co-morbidities

          -  less than 3 months old or older than 18 years of age

          -  non-english speaking

          -  on antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Peter, MD</last_name>
    <role>Study Director</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008 Mar;51(3):291-8. doi: 10.1016/j.annemergmed.2007.12.004. Epub 2008 Jan 28.</citation>
    <PMID>18222564</PMID>
  </reference>
  <reference>
    <citation>Korownyk C, Allan GM. Evidence-based approach to abscess management. Can Fam Physician. 2007 Oct;53(10):1680-4. Review.</citation>
    <PMID>17934031</PMID>
  </reference>
  <reference>
    <citation>Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol. 2007;8(5):259-70. Review.</citation>
    <PMID>17902728</PMID>
  </reference>
  <reference>
    <citation>Lee MC, Rios AM, Aten MF, Mejias A, Cavuoti D, McCracken GH Jr, Hardy RD. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004 Feb;23(2):123-7.</citation>
    <PMID>14872177</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <results_first_submitted>January 29, 2013</results_first_submitted>
  <results_first_submitted_qc>March 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2014</results_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin abscess</keyword>
  <keyword>CA-MRSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Simethicone</mesh_term>
    <mesh_term>Aluminum hydroxide, magnesium hydroxide, drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients &gt;3months and &lt;18 years old with skin abscesses who are not immunocompromised, or in 3rd trimester of pregnancy were approached to participate in the study, or allergic to trimethoprim/sulfamethoxazole.</recruitment_details>
      <pre_assignment_details>Enrolled participants were only excluded from the trial before assignment to groups if they left the emergency department prior to receiving the medication/placebo and further instructions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Group</title>
          <description>Maalox and bitter mixture</description>
        </group>
        <group group_id="P2">
          <title>Antibiotic Group</title>
          <description>Trimethoprim-sulfamethoxazole suspension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Group</title>
          <description>Maalox and bitter mixture</description>
        </group>
        <group group_id="B2">
          <title>Antibiotic Group</title>
          <description>Trimethoprim-sulfamethoxazole suspension</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="161"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="0.5"/>
                    <measurement group_id="B2" value="4.5" spread="0.5"/>
                    <measurement group_id="B3" value="4.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Skin Abscess Resolution</title>
        <time_frame>10-14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Maalox and bitter mixture</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic Group</title>
            <description>Trimethoprim-sulfamethoxazole suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Abscess Resolution</title>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1.2" upper_limit="6.8"/>
                    <measurement group_id="O2" value="3" lower_limit="1.2" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Lesion Development and Spread of Skin Abscesses (on Subject)</title>
        <description>The secondary outcomes of interest included the development of new lesions at a different site (&gt;5cm away from original skin abscess) on day 10 clinical follow-up or self-report and 3 month telephone follow-up.</description>
        <time_frame>10-14 days and 3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Maalox and bitter mixture</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic Group</title>
            <description>Trimethoprim-sulfamethoxazole suspension</description>
          </group>
        </group_list>
        <measure>
          <title>New Lesion Development and Spread of Skin Abscesses (on Subject)</title>
          <description>The secondary outcomes of interest included the development of new lesions at a different site (&gt;5cm away from original skin abscess) on day 10 clinical follow-up or self-report and 3 month telephone follow-up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants were called 2-3 days later to set up follow up at day 10-14 and enquiries are made regarding any medication side effects. Phone calls were made 3 months later for further follow ups on recurrences and if other family members had developed skin abscesses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Group</title>
          <description>Maalox and bitter mixture</description>
        </group>
        <group group_id="E2">
          <title>Antibiotic Group</title>
          <description>Trimethoprim-sulfamethoxazole suspension</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>vomiting and diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>bad taste</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <description>any rash other than a pustule, folliculitis, carbuncle or skin abscess</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size with large number of loss to follow up at the 3 month mark.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Myto Duong, Pediatric Emergency Medicine Director</name_or_title>
      <organization>Southern Illinois University, School of Medicine</organization>
      <phone>217-545-7409</phone>
      <email>myto_duong@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

